Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.72 |
| ▸ | BCHE | P06276 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7364408 | 0.85 | MAPT (0.74) | MAPTALDH1A1NPC1RAB9ACHRNA7 | |
| SCHEMBL13595966 | 0.85 | MAPT (0.74) | MAPTALDH1A1NPC1RAB9ACHRNA7 | |
| SCHEMBL7365487 | 0.85 | MAPT (0.74) | MAPTALDH1A1NPC1RAB9ACHRNA7 | |
| SCHEMBL4408602 | 0.85 | ALDH1A1 (1.00) | MAPTALDH1A1NPC1RAB9ACHRNA7 | |
| SCHEMBL7358272 | 0.84 | NPC1 (1.00) | MAPTALDH1A1NPC1RAB9ACHRNA7 | |
| SCHEMBL372135 | 0.84 | CHRNA7 (1.00) | MAPTALDH1A1NPC1RAB9ACHRNA7 | |
| SCHEMBL372949 | 0.84 | CHRNA7 (1.00) | MAPTALDH1A1NPC1RAB9ACHRNA7 | |
| SCHEMBL373197 | 0.84 | CHRNA7 (1.00) | MAPTALDH1A1NPC1RAB9ACHRNA7 | |
| SCHEMBL373320 | 0.84 | CHRNA7 (0.79) | MAPTALDH1A1NPC1RAB9ACHRNA7 | |
| SCHEMBL13595715 | 0.84 | CHRNA7 (0.79) | MAPTALDH1A1NPC1RAB9ACHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066486-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066486-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-06 | — | — | US | disclosed |
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-05-19 | — | — | US | disclosed |
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-05-19 | — | — | US | disclosed |
| EP-0885221-B1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | ASTRAZENECA AB (SE) | 2002-06-12 | — | — | EP | disclosed |
| US-6054464-A | Azabicyclic esters of carbamic acids useful in therapy | ASTRA AKTIEBOLAG (SE) | 2000-04-25 | — | — | US | disclosed |
| US-5998429-A | Azabicyclic esters of carbamic acids useful in therapy | ASTRA AB (SE) | 1999-12-07 | — | — | US | disclosed |
| EP-0885221-A1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | Astra Aktiebolag (SE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030998-A1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | REL, RCOR3, RBBP4 | MAPT 2163/4885ALDH1A1 4382/4885NPC1 1943/4885 |
| US-20140066486-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | REL, RCOR3, RBBP4 | MAPT 2163/4885ALDH1A1 4382/4885NPC1 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.